The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
